重症COVID-19患者HSV-1再激活与死亡和肺炎风险增加相关
该观察性研究纳入单中心153例住院≥48小时的重症COVID-19患者,采用前瞻性收集的HSV-1血液和呼吸道样本数据。40/153(26.1%)患者确认HSV-1再激活。再激活组60天死亡率57.5%,未再激活组33.6%(p=0.001)。多因素校正后,HSV-1再激活与死亡风险增加相关(HR 2.05;95%CI 1.16-3.62;p=0.01),并与HAP/VAP风险增加相关(csHR 2.38,95%CI 1.06-5.39,p=0.037),但与ICU血流感染无显著关联。
要点
- 153例重症COVID-19患者中40例(26.1%)确认HSV-1再激活,再激活组60天死亡率57.5% vs 未再激活组33.6%(p=0.001)。
- 多因素校正后HSV-1再激活与死亡风险增加独立相关(HR 2.05;95%CI 1.16-3.62;p=0.01)。
- HSV-1再激活与HAP/VAP风险增加相关(csHR 2.38,95%CI 1.06-5.39,p=0.037)。
- HSV-1再激活与ICU血流感染无显著关联(多因素病因特异性模型)。
- HAP/VAP总发生率43.8%(67/153),ICU-BSI总发生率27.5%(42/153)。
适用人群与场景
- 2020年2月至2021年2月在一家大型参考中心收治的、住院时间≥48小时的重症COVID-19成人患者,且进行了HSV检测。
研究设计与关键结果
- 观察性研究,使用前瞻性收集的数据及HSV-1血液和呼吸道样本,纳入153例住院≥48小时的重症COVID-19患者。
- 40/153(26.1%)患者确认HSV-1再激活;其中呼吸道样本HSV阳性19/61(31.1%),血液样本HSV阳性36/146(24.7%)。
- HSV-1再激活组60天死亡率为57.5%,未再激活组为33.6%(p=0.001)。
- 多因素Cox模型校正死亡危险因素后,HSV-1再激活与死亡风险增加相关(HR 2.05;95%CI 1.16-3.62;p=0.01)。
- HAP/VAP发生于67/153(43.8%)患者,ICU-BSI发生于42/153(27.5%)患者。
- 多因素病因特异性模型显示,HSV-1再激活患者HAP/VAP风险增加(csHR 2.38,95%CI 1.06-5.39,p=0.037),ICU-BSI风险无显著增加。
证据类型、等级与局限
- 证据类型:观察性研究,使用前瞻性收集的数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在重症COVID-19患者中,HSV-1再激活与60天死亡率和HAP/VAP风险增加相关,提示对这类患者应关注HSV-1再激活的检测与评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Data in the literature about HSV reactivation in COVID-19 patients are scarce, and the association between HSV-1 reactivation and mortality remains to be determined. Our objectives were to evaluate the impact of Herpes simplex virus (HSV) reactivation in patients with severe SARS-CoV-2 infections primarily on mortality, and secondarily on hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) and intensive care unit-bloodstream infection (ICU-BSI).
METHODS: We conducted an observational study using prospectively collected data and HSV-1 blood and respiratory samples from all critically ill COVID-19 patients in a large reference center who underwent HSV tests. Using multivariable Cox and cause-specific (cs) models, we investigated the association between HSV reactivation and mortality or healthcare-associated infections.
RESULTS: Of the 153 COVID-19 patients admitted for ≥ 48 h from Feb-2020 to Feb-2021, 40/153 (26.1%) patients had confirmed HSV-1 reactivation (19/61 (31.1%) with HSV-positive respiratory samples, and 36/146 (24.7%) with HSV-positive blood samples. Day-60 mortality was higher in patients with HSV-1 reactivation (57.5%) versus without (33.6%, p = 0.001). After adjustment for mortality risk factors, HSV-1 reactivation was associated with an increased mortality risk (hazard risk [HR] 2.05; 95% CI 1.16-3.62; p = 0.01). HAP/VAP occurred in 67/153 (43.8%) and ICU-BSI in 42/153 (27.5%) patients. In patients with HSV-1 reactivation, multivariable cause-specific models showed an increased risk of HAP/VAP (csHR 2.38, 95% CI 1.06-5.39, p = 0.037), but not of ICU-BSI.
CONCLUSIONS: HSV-1 reactivation in critically ill COVID-19 patients was associated with an increased risk of day-60 mortality and HAP/VAP.
参考来源
- Meyer A, Buetti N, Houhou-Fidouh N, et al. HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients. Crit Care. 2021. PMID: 34872611. doi:10.1186/s13054-021-03843-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。